Haylief Hayfever & Allergy 10mg Tablets
Out of date information, search anotherSUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE MEDICINAL PRODUCT
Relonchem Hayfever & Allergy 10mg tablets Bell’s Healthcare Hayfever & Allergy 10mg tablets Peach Hayfever & Allergy 10mg tablets Alexander’s Hayfever & Allergy 10mg tablets Haylief Hayfever & Allergy 10mg Tablets Tesco One a day Hayfever & Allergy 10mg Tablets Essential Waitrose Hayfever & Allergy 10mg tablets
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 10mg loratadine.
For excipients see 6.1.
3 PHARMACEUTICAL FORM
Tablet.
Appearance: white, round, flat tablets with a scoreline
4 CLINICAL PARTICULARS
4.1 Therapeutic indications
Relonchem Hayfever and Allergy 10mg tablets are indicated for the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria.
4.2 Posology and method of administration
Adults, including the elderly, and children 12 years of age and over:
One 10 mg tablet once daily Children 2 to 12 years of age with:
Body weight more than 30 kg: 10 mg once daily (one tablet)
Body weight 30 kg or less: 5 ml (5 mg) of the syrup once daily. The 10 mg strength tablet is not
appropriate in children with a body weight less than 30 kg.
Efficacy and safety of Loratadine 10 mg Tablets in children under 2 years of age has not been
established in this age group.
Patient with severe liver impairment should be administered a lower intial dose because they may
have reduced clearance of loratadine. An initial dose of 10 mg every other day is recommended
for adults and children weighing more than 30 kg, and for children weighing 30 kg or less, 5 ml
(5 mg) every other day is recommended.
No dosage adjustments are required in the elderly or in patients with renal insufficiency
4.3 Contraindications
Relonchem Hayfever and Allergy 10mg tablets are contraindicated in patients who are hypersensitive to the active substance or to any of the excipients.
4.4 Special warnings and precautions for use
Relonchem Hayfever and Allergy 10mg tablets should be administered with caution in patients with severe liver impairment (see 4.2)
Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or
glucose-galactose malabsorption should not take this medicine.
The administration of Relonchem Hayfever and Allergy 10mg tablets should be discontinued at least 48 hours before skin tests since antihistamines may prevent or reduce otherwise positive reactions to dermal reactivity index.
4.5 Interaction with other medicinal products and other forms of interaction
When administered concomitantly with alcohol, Relonchem Hayfever and Allergy 10mg tablet has no potentiating effects as measured by psychomotor performance studies.
Due to the wide therapeutic index of loratadine no clinically relevant interactions are expected
and none were observed in the conducted clinical trials (see 5.2).
Loratadine is metabolised by hepatic CYP3A4 and CYP2D6 isoenzymes. Increase in plasma concentrations of loratadine has been reported after concomitant use with ketoconazole,
erythromycin and cimetidine in controlled trials, but without clinically significant changes
(including electrocardiographic).
4.6 Fertility, pregnancy and lactation
Loratadine was not teratogenic in animal studies. The safe use of loratadine during pregnancy has
not been established. The use of Relonchem Hayfever and Allergy 10mg tablets during pregnancy is therefore not recommended.
Loratadine is excreted in breast milk, therefore the use of loratadine is not recommended in
breast-feeding women.
4.7 Effects on ability to drive and use machines
In clinical trials that assessed driving ability, no impairment occurred in patients receiving
loratadine. However, patients should be informed that very rarely some people rarely experience
drowsiness, which may affect their ability to drive or use machines.
4.8 Undesirable effects
In clinical trials in a paediatric population, children aged 2 through 12 years, common adverse
reactions reported in excess of placebo were headache (2.7%), nervousness (2.3%), and fatigue
(1%).
In clinical trials involving adults and adolescents in a range of indications including AR and CIU,
at the recommended dose of 10 mg daily, adverse reactions with loratadine were reported in 2%
of patients in excess of those treated with placebo. The most frequent adverse reactions reported
in excess of placebo were somnolence (1.2%), headache (0.6%), increased appetite (0.5%) and
insomnia (0.1%). Other adverse reactions reported very rarely during post marketing period are listed in the following table.
|
Immune disorders |
Anaphylaxis |
|
Nervous System disorders |
Dizziness |
|
Cardiac disorders |
Tachycardia, palpitation |
|
Gastrointestinal disorders |
Nausea, dry mouth, gastritis |
|
Hepato-bilary disorders |
Abnormal hepatic function |
|
Skin and subcutaneous tissue disorders |
Rash, alopecia |
|
General disorders and administration site Conditions |
Fatigue |
4.9 Overdose
Overdosage with loratadine increased the occurrence of anticholinergic symptoms. Somnolence,
tachycardia and headache have been reported with overdoses.
In the event of overdose, general symptomatic and supportive measures are to be instituted and
maintained for as long as necessary. Administration of activated charcoal as a slurry with water
may be attempted. Gastric lavage may be considered. Loratadine is not removed by
haemodialysis and it is not known if loratadine is removed by peritoneal dialysis. Medical
monitoring of the patient is to be continued after emergency treatment.
5 PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: antihistamines - H1 antagonist, ATC code: R 06 AX 13
Loratadine the active ingredient in Relonchem Hayfever and Allergy 10mg tablets is a tricyclic antihistamine with selective, peripheral H1-receptors activity.
Loratadine has no clinically significant sedative or anticholinergic properties in the majority of
the population and when used at the recommended dosage.
During long-term treatment there were no clinically significant changes in vital signs, laboratory
test values, physical examinations of electrocardiograms.
Loratadine has no significant H2-receptor activity. It does not inhibit noradrenaline uptake and
has practically no influence on cardiovascular function or on intrinsic cardiac pacemaker activity.
5.2 Pharmacokinetic properties
After oral administration, loratadine is rapidly and well and undergoes an extensive first pass
metabolism, mainly by CYP 3A4 and CYP 2D6. The major metabolite -desloratadine (DL) - is
pharmacologically active and responsible for a large part of clinical effect. Loratadine and DL
achieve maximum plasma concentrations (Tmax) between 1 - 1.5 hours and 1.5 - 3.7 hours after
administration, respectively.
Increase in plasma concentrations of loratadine has been reported after concomitant use with
ketoconazole, erythromycin and cimetidine in controlled trials, but without clinically significant
changes (including electrocardiography).
Loratadine is highly bound (97% to 99%) and its active metabolite moderately bound (73% to
76%) to plasma proteins.
In healthy subjects, plasma distribution half-lives for loratadine and its active metabolite are approximately 1 and 2 hours, respectively. The mean elimination half-lives in healthy adult
subjects were 8.4 hours (range = 3 to 20 hours) for loratadine and 28 hours (range = 8.8 to 92
hours) for the major active metabolite.
Approximately 40% of the dose is excreted in the urine and 42% in the faeces over a 10-day
period (mainly in the form of conjugated metabolites). Approximately 27% of the dose is
eliminated in the urine during the first 24 hours. Less than 1% of the active substance is excreted
unchanged in active form, as loratadine or DL.
The bioavailability parameters of loratadine and of the active metabolite are dose proportional.
The pharmacokinetic profile of loratadine and its metabolites is comparable in healthy adult
volunteers and healthy geriatric volunteers.
Concomitant ingestion of food can delay slightly the absorption of loratadine but without
influencing the clinical effect.
In patients with chronic renal impairment, both the AUC and the peak plasma levels (Cmax)
increased for loratadine and its metabolite as compared with the AUCs and Cmax of patients with
normal renal function. The mean elimination half-lives of loratadine and its metabolite were not
significantly different from that observed in normal subjects. Haemodialysis does not have an
effect on the pharmacokinetic profile of loratadine or its active metabolite in subjects with
chronic renal impairment.
In patients with chronic alcoholic liver disease, the AUC and Cmax of loratadine were double
while the pharmacokinetic profile of the active metabolite was not significantly changed from
that in patients with normal liver function. The elimination half-lives for loratadine and its metabolite were 24 hours and 37 hours, respectively, and increased with increasing severity of
liver disease.
Loratadine and its active metabolite are excreted in the breast milk of lactating women.
5.3 Preclinical safety data
Preclinical data reveal no special hazard based on conventional studies of safety, pharmacology,
repeated dose toxicity, genotoxicity and carcinogenic potential.
In reproductive toxicity studies, no teratogenic effects were observed. However, prolonged
parturition and reduced viability of offspring were observed in rats at plasma levels (AUC) 10
times higher than those achieved with clinical doses.
No evidence of mucous membrane irritation was observed after daily administration of up to 12
tablets (120 mg) of oral lyophilisates into the hamster cheek pouch for five days.
6 PHARMACEUTICAL PARTICULARS
6.1 List of excipients
Lactose monohydrate Microcrystalline cellulose Maize starch Magnesium stearate
6.2 Incompatibilities
Not applicable
6.3 Shelf life
3 years
6.4 Special precautions for storage
None
6.5 Nature and contents of container
Packages with 7, 10, 14 and 30 tablets in blister packs (PVC/aluminium)
6.6 Special precautions for disposal
No special instructions
7 MARKETING AUTHORISATION HOLDER
Relonchem Limited Cheshire House, Gorsey Lane,
Widnes, Cheshire,
WA8 0RP,
United Kingdom
8 MARKETING AUTHORISATION NUMBER(S)
PL 20395/0088
9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
03/04/2012
10 DATE OF REVISION OF THE TEXT
07/08/2014